398 related articles for article (PubMed ID: 28661711)
1. Safety of ixazomib for the treatment of multiple myeloma.
Bonnet A; Moreau P
Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Salvini M; Troia R; Giudice D; Pautasso C; Boccadoro M; Larocca A
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):91-99. PubMed ID: 29235380
[TBL] [Abstract][Full Text] [Related]
3. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
4. Oral ixazomib maintenance therapy in multiple myeloma.
Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
7. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
8. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
10. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
13. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Smolewski P; Rydygier D
Expert Opin Investig Drugs; 2019 May; 28(5):421-433. PubMed ID: 30907163
[TBL] [Abstract][Full Text] [Related]
16. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib: a novel drug for multiple myeloma.
Zanwar S; Abeykoon JP; Kapoor P
Expert Rev Hematol; 2018 Oct; 11(10):761-771. PubMed ID: 30173621
[TBL] [Abstract][Full Text] [Related]
18. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
19. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Jouni H; Aubry MC; Lacy MQ; Vincent Rajkumar S; Kumar SK; Frye RL; Herrmann J
Am J Hematol; 2017 Feb; 92(2):220-221. PubMed ID: 27859518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
